2025-04-11 - Analysis Report
## Recursion Pharmaceuticals Inc. (RXRX) Stock Report

**0. Key Figures Summary:**

* **Current Price:** $4.51
* **Cumulative Return (RXRX):** -51.9%
* **Cumulative Return (VOO):** 11.05%
* **Return Difference (RXRX vs VOO):** -63.0%
* **Relative Divergence:** 7.8% (Indicates RXRX significantly underperformed VOO relative to historical volatility)
* **RSI:** 23.79 (Oversold territory)
* **PPO:** -2.20 (Negative, indicating bearish momentum)
* **Market Risk Indicator (MRI):** 0.43 (Medium Risk)


**1. Performance Comparison & Company Overview:**

Recursion Pharmaceuticals Inc. (RXRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence to discover and develop new drugs.  RXRX has significantly underperformed the S&P 500 (VOO) over the analyzed period, with a cumulative return of -51.9% compared to VOO's 11.05%.  The -63% difference places its performance in the 7.8th percentile of its historical range relative to VOO,  indicating a substantial underperformance.

Alpha and Beta Analysis:

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -10.0% | 4.1 |
| 2022-2024  | 0.0% | 73.6% | -21.0% | 2.8 |
| 2023-2025  | 0.0% | 73.6% | -11.0% | 1.9 |

The consistently negative alpha values suggest underperformance against the market benchmark.  The high beta values (above 1) demonstrate significant volatility, with RXRX's price movements exceeding those of the market.  Market capitalization has been steadily decreasing.


**2. Recent Price Movement:**

* **Closing Price:** $4.51
* **Previous Close:** $4.65
* **5-Day Moving Average:** $4.31
* **20-Day Moving Average:** $5.63
* **60-Day Moving Average:** $6.94

The current price is below all three moving averages, indicating a downtrend. The recent price drop of -3.01% from the previous close signals further downward pressure.


**3. Technical Indicators & Expected Return:**

* **RSI (23.79):**  Indicates the stock is significantly oversold, suggesting potential for a rebound, although not guaranteeing it.
* **PPO (-2.20):**  Shows negative momentum, confirming the bearish trend.
* **Delta_Previous_Relative_Divergence (-0.7):**  Shows a recent short-term downward trend.
* **Market Risk Indicator (MRI):** 0.43 suggests a medium level of risk.
* **Expected Return (-420.3%):**  This extremely negative expected return relative to the S&P 500 over the long term (2+ years) raises significant concerns about future prospects. The large negative value warrants further investigation into the reasons behind this prediction.  This is likely driven by the current poor performance and negative outlook.



**4. Recent Earnings Analysis:**

| Date       | EPS      | Revenue      |
|------------|----------|--------------|
| 2024-11-06 | -$0.34   | $0.03 B      |
| 2024-08-08 | -$0.40   | $0.01 B      |
| 2024-05-09 | -$0.39   | $0.01 B      |
| 2023-11-09 | -$0.43   | $0.01 B      |
| 2024-11-06 | -$0.43   | $0.01 B      | *(Duplicate entry, likely a data error)*


Consistent negative EPS indicates ongoing losses.  Revenue is low and relatively stagnant, raising concerns about the company's ability to generate sufficient income.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.00B | -183.62% |
| 2024-09-30 | $0.03B | 53.69% |
| 2024-06-30 | $0.01B | 36.14% |
| 2024-03-31 | $0.01B | 17.23% |
| 2023-12-31 | $0.01B | 6.99% |

Highly erratic profit margins highlight significant financial instability. The extremely negative margin in Q4 2024 is particularly alarming.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $1.03B | -17.29% |
| 2024-09-30 | $0.52B | -18.27% |
| 2024-06-30 | $0.58B | -16.69% |
| 2024-03-31 | $0.40B | -22.78% |
| 2023-12-31 | $0.46B | -20.07% |

Negative ROE consistently indicates that the company is not generating sufficient returns on its equity.  Fluctuations in equity suggest financial instability.


**6. Overall Analysis:**

Recursion Pharmaceuticals (RXRX) shows significant financial distress, with consistent losses, low and volatile revenue, negative profit margins, and negative ROE.  The stock has dramatically underperformed the S&P 500, and technical indicators point towards a bearish trend.  The extremely negative projected long-term return raises serious concerns about its investment viability.  Further investigation into the reasons behind the substantial losses and low revenue is crucial before considering any investment.  The current situation suggests a high-risk investment with limited upside potential.  Investors should proceed with extreme caution.
